| Autor: |
Mailankody S; Myeloma Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mailanks@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. mailanks@mskcc.org., Matous JV; Colorado Blood Cancer Institute, Denver, CO, USA., Chhabra S; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Liedtke M; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA., Sidana S; Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University Hospital, Stanford, CA, USA., Oluwole OO; Vanderbilt University Medical Center, Nashville, TN, USA., Malik S; Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX, USA., Nath R; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Anwer F; Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA., Cruz JC; Texas Transplant Institute, San Antonio, TX, USA., Htut M; Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, USA., Karski EE; Allogene Therapeutics, South San Francisco, CA, USA., Lovelace W; Allogene Therapeutics, South San Francisco, CA, USA., Dillon M; Allogene Therapeutics, South San Francisco, CA, USA., Butz E; Allogene Therapeutics, South San Francisco, CA, USA., Ying W; Allogene Therapeutics, South San Francisco, CA, USA., Balakumaran A; Allogene Therapeutics, South San Francisco, CA, USA., Kumar SK; Mayo Clinic, Rochester, MN, USA. |
Full text from SpringerLink